Short Bowel Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

January 25 23:26 2023
Short Bowel Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
Short Bowel Syndrome Pipeline Insights
DelveInsight’s ‘Short Bowel Syndrome Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline Short Bowel Syndrome therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Short Bowel Syndrome pipeline domain.

United States, Nevada, Las Vegas, DelveInsight’s Short Bowel Syndrome Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Short Bowel Syndrome therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Short Bowel Syndrome pipeline domain.

Key Takeaways from the Short Bowel Syndrome Pipeline Report

  • Over 20+ Short Bowel Syndrome pipeline therapies are in various stages of development, and their anticipated acceptance in the Short Bowel Syndrome market would significantly increase market revenue. 
  • Leading Short Bowel Syndrome companies developing novel drug candidates to improve the Short Bowel Syndrome treatment landscape include Zealand Pharma, and others.
  • Promising Short Bowel Syndrome pipeline therapies in various stages of development include Glepaglutide, and others.

Short Bowel Syndrome Overview

Short bowel syndrome (SBS) in adults is defined as less than 180 to 200 centimeters of remaining small bowel (normal length 275 to 850 cm) leading to the need for nutritional and fluid supplements. Short bowel syndrome may be classified as a cause or subcategory of intestinal failure. In rare cases, infants are born with a short bowel (congenital short bowel syndrome). Although these congenital cases are often associated with malrotation of the small intestine, the exact cause of congenital short bowel syndrome is unknown. The main cause of short bowel syndrome is surgery to remove a portion of the small intestine. This surgery can treat intestinal diseases, injuries, or birth defects. Some children are born with an abnormally short small intestine or a missing part of their bowel, which can cause short bowel syndrome. In infants, short bowel syndrome most commonly occurs following surgery to treat necrotizing enterocolitis, a condition in which part of the tissue in the intestines is destroyed

Short Bowel Syndrome Pipeline Analysis: Drug Profile

Glepaglutide: Zealand Pharma

Glepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome (SBS). Glepaglutide is being developed as a liquid product in an autoinjector designed for subcutaneous administration, aimed to reduce, or eliminate, the need for parenteral support in people living with SBS. Currently the product is in Phase III stage of development for the treatment of Short Bowel Syndrome 

Discover more about the emerging Short Bowel Syndrome drugs @ Short Bowel Syndrome Treatment Drugs

Short Bowel Syndrome Key Companies

  • Zealand Pharma

Short Bowel Syndrome Pipeline Therapies

  • Glepaglutide

Short Bowel Syndrome Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Short Bowel Syndrome Pipeline Report 

  • Coverage: Global 
  • Key Short Bowel Syndrome Companies: Zealand Pharma, and others
  • Key Short Bowel Syndrome Pipeline Therapies: Glepaglutide, and others

Find out more about the Short Bowel Syndrome treatment options in development @ Short Bowel Syndrome Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies working in the Short Bowel Syndrome pipeline domain.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/